Social media

ICON will be at #EBF, 18–20 November. Visit booth B-15 to meet our bioanalytical experts and learn how we support drug development with regulatory-compliant solutions. https://ow.ly/L0x150XiU3t

Antibody-drug conjugates (ADCs) are transforming cancer treatment — but measuring free payload concentrations is critical to ensure their safety and efficacy. Even the smallest impurity can skew results. Discover how adv...

Implementing digital health technologies in clinical trials is promising, but doing it well means more than just selecting the right tools. From training and compliance monitoring to real-time data readiness, success de...

Clinical development is under pressure: rising costs, long timelines, complex designs. The solution? A digitally enabled, patient-centered approach. In this whitepaper, we explore how Digital Health Technologies are tra...

Pregnant women remain significantly underrepresented in clinical trials, leading to critical data gaps in drug safety and efficacy. ICON’s Liz O’Brien underscores the importance of building trust, fostering transparency,...

The specific needs of oncology clinical trials, alongside the distinct clinical pathway for biosimilars, mean that developing these treatments must be approached very differently from novel biologic development. To under...

Oncology biosimilars present unique potential and distinct challenges to sponsors. The specific needs of oncology clinical trials, alongside the distinct clinical pathway for biosimilars, mean that developing these tre...

Metabolic dysfunction-associated steatohepatitis (MASH) is rapidly becoming one of the leading causes of liver-related morbidity and mortality — yet it remains underdiagnosed and under-recognised. In our latest blog, fr...

Did you know? MASH (Metabolic dysfunction-associated steatohepatitis) is a progressive liver disease affecting millions — and most don’t even know they have it. Our new blog from Symphony Health, an ICON plc company, d...

ICON is pleased to announce our participation at the upcoming #OCTDACH conference, taking place on 12–13 November at the Kameha Grand in Zurich, Switzerland. We invite you to visit us at booth #8 to learn how we can he...

It was a pleasure for us to connect with so many attendees on Day 1 of #CPHIFrankfurt. We appreciated the opportunity to share how ICON is driving innovation across clinical research, commercialization, and digital healt...

ICON will attend the 18th EBF Open Symposium, taking place from 18–20 November at the Hyatt Regency Barcelona Tower. Join us at booth B-15 to meet our experts and learn how ICON delivers high-quality bioanalytical solut...